Direxion Daily CSI China Internet Bull 2X Shares vs Ginkgo Bioworks Holdings Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.26 (market cap $176.60M), while Ginkgo Bioworks Holdings Inc trades at $11.59 (market cap $772.39M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 4.4× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| CWEB | DNA | |
|---|---|---|
Market Cap | $176.60M | $772.39M |
Volume | 440,349 | 6,453,273 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $15.83 |
52-Week Low | $17.39 | $5.48 |
Typical Hold Time | 24 Days | 7 Days |
Enterprise Value | — | $874.34M |
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $18.02, down 1.85% today amid bearish technical signals. The stock shows weak momentum with all 13 moving averages signaling sell, though oscillators are neutral. Recent news highlights China's AI ambitions and potential for China growth stocks to surge, providing thematic catalysts. Financial ratios remain undisclosed in current data.
Outlook hinges on China's tech sector recovery and AI growth narrative. Risks include geopolitical tensions and market volatility. The upcoming dividend of $0.07 in September 2026 offers income potential, but investors need clarity on fundamentals for sustained upside.
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →